Skip to playerSkip to main content
  • 2 days ago
Hims stock isn’t the whole story—the real test is whether digital healthcare demand becomes a durable business. Hims investor relations points to Hers Health’s reported second-quarter 2026 results as fresh evidence, not another LinkedIn growth story. Revenue quality, margins, and guidance will show whether Hims is building a healthcare platform or selling attention at a premium. Pick a side in the comments: healthcare platform or expensive hype?

Category

🤖
Tech
Transcript
00:00HIMS stock isn't the whole story everyone's watching the ticker the real question can HIMS
00:08turn digital health care demand into a durable business HIMS investor relations says hers
00:14health reported second quarter 2026 results fresh operating data not another LinkedIn growth story
00:23revenue quality margins and guidance decide whether HIMS is a health care platform
00:28or an expensive attention machine is HIMS building health care or selling height pick a side
Comments

Recommended